Therefore, we explored the interrelationship between CDK4/6 inhibitors and mTOR inhibitors in ccRCC and discovered that the RNF26/TSC1 axis plays a bridging role between the CDK4 and mTOR signaling pathways. This evidence concerns the gene CDK4 and nonpapillary renal cell carcinoma.